Drug Profile


Alternative Names: Traxanox sodium; Traxanox sodium pentahydrate; Y 12141; YZ 12141

Latest Information Update: 28 Nov 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Antiallergics; Antiasthmatics; Antibronchitics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Allergic rhinitis; Asthma

Most Recent Events

  • 28 Nov 1997 No-Development-Reported for Allergic rhinitis in Japan (Unknown route)
  • 28 Nov 1997 No-Development-Reported for Asthma in Japan (Unknown route)
  • 23 Feb 1995 Investigation in Allergic rhinitis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top